Opportunity Analyzer: Idiopathic Pulmonary Fibrosis - Opportunity Analysis and Forecast to 2025
The IPF therapeutic market is currently dominated by the only two drugs that have gained marketing approval for IPF - Roche’s Esbriet and Boehringer Ingelheim’s Ofev. Esbriet was the first drug to gain approval for IPF in 2011 when it was approved for use in Europe, a full four years before rival Ofev. However, both gained approval into the largest IPF market of the US on the same day in October 2014. The top-selling drug in IPF in value terms is Roche’s Esbriet, which GlobalData estimates generated approximately $572m in 2015 from the seven major markets. There is high R&D activity for the development of new therapies for IPF and eight promising therapies can potentially enter the market from 2015 to 2025. Numerous novel targets are being studied in the IPF pipeline, with major pharmaceutical players Roche, Sanofi, Bristol-Myers Squibb, and Biogen all active in the development process. Other promising pipeline candidates include FibroGen’s CTGF inhibitor, Promedior’s PTX2 protein, Afferent’s P2X3 receptor antagonist, and MediciNova’s 5-LO/LT pathway inhibitor. The continued uptake of Esbriet and Ofev, combined with the introduction of new novel drugs will shape the future competitive landscape and drive growth in the IPF market.
Key Questions Answered
- What was the impact of Esbriet and Ofev on the IPF market following their FDA approval in 2014 and what is their future outlook within this market? - What do physicians think about Esbriet and Ofev, and how they will be used for IPF during the forecast period? - What is the significance of late-phase pipeline products and how will their launch shape the future treatment landscape in IPF? - What are the unmet needs within the IPF market? - What are the remaining opportunities within the IPF market?
- The main drivers of growth for the IPF market include the increasing uptake of Esbriet and Ofev, the launch of new novel treatment options during the second half of the forecast period, and the increasing number of prevalent cases of IPF. - R&D strategies include the development of novel therapies, partnerships and acquisitions, combination of therapies, and targeting niche patient subpopulations. - The IPF therapeutic market is characterized by significant unmet needs. The most pressing unmet need is the development of a product capable of either stabilizing or reversing progression of IPF. Current therapies Esbriet and Ofev do not address this need and are only capable of slowing disease progression. - With high R&D activity in the IPF therapeutic market, physicians are looking forward to pipeline products becoming available, which will enable them to improve patients’ treatment.
- Overview of IPF, including epidemiology, etiology, pathophysiology, symptoms, diagnosis, and current treatment options. - Annualized IPF therapeutic market revenue, annual cost of therapy and treatment usage pattern data from 2015 and forecast for ten years to 2025. - Key topics covered include strategic competitor assessment, market characterization, unmet needs, and implications for the IPF therapeutics markets. - Pipeline analysis: comprehensive data split across different phases, emerging novel trends under development, and detailed analysis of mid-stage pipeline drugs. - Analysis of the current and future market competition in the global IPF therapeutics markets. Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications.
Reasons to buy
The report will enable you to - - Develop and design in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline. - Develop business strategies by understanding the trends shaping and driving the global IPF therapeutic markets. - Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the global IPF therapeutic markets in the future. - Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors. - Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage. - Track drug sales in the global IPF therapeutic markets from 2015-2025. - Organize sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.
Our reports have been used by over 10K customers, including:
An ear infection occurs when a bacterial or viral infection that affects the inner, middle or outer ear. Ear infections can be painful because of inflammation and fluid buildup in the ear. Acute ear infection can cause mild pain and discomfort in the ear. However chronic cases can cause severe pain, loss of body balance, drainage of fluids...
The global injection pens market is projected to reach USD 53.3 billion by 2026 from USD 37.6 billion in 2021, at a CAGR of 7.2% during the forecast period. Growing prevalence of chronic diseases, increasing number of regulatory approvals, favourable reimbursement and government support, and technological advancements in injection pens tend...
The Urinary Tract Infection Therapeutics Market is expected to register a CAGR of 4.1% during the forecast period. Certain factors that are driving the market growth include the increasing prevalence of diabetes and kidney stones and the launch of combination drugs. Key Highlights According to a study published...
The hematuria treatment market is projected to reach US$ 1,103.61 million by 2028 from US$ 932.89 million in 2021; it is estimated to grow at a CAGR of 2.4% from 2021 to 2028. Factors such as the high prevalence of hematuria-associated indications, and increasing awareness about treatment options and improving healthcare expenditure are driving...
175 pages •
By The Business Research Company
• Sep 2021
Major players in the biosimilar therapeutic peptides market are Eli Lilly, Sanofi, Takeda Pharmaceuticals, Teva Pharmaceuticals, Pfizer Inc., Amgen Inc., AstraZeneca PLC, GlaxoSmithKline (GSK), Novartis AG, and Novo Nordisk A/S. The global biosimilar therapeutic peptides market is expected to grow from $0.76 billion in 2020 to $0.87...
Insulin Like Growth Factor I (Mechano Growth Factor or Somatomedin C or IGF1) - Drugs in Development, 2021 Summary According to the recently published report ’Insulin Like Growth Factor I - Drugs In Development, 2021’; Insulin Like Growth Factor I (Mechano Growth Factor or Somatomedin C or IGF1)...
Retinoic Acid Receptor Gamma - Drugs In Development, 2021 Summary Retinoic Acid Receptor Gamma (RAR Gamma or Nuclear Receptor Subfamily 1 Group B Member 3 or NR1B3 or RARG) - Retinoic acid receptor gamma (RARG) is a nuclear receptor that is encoded by the RARG gene. RARG bind as heterodimers to the...
Executive Summary The Global Peptide Therapeutics Market is valued at USD 32.1 Billion in the year 2020. The growth of Peptide Therapeutics is directly associated with drug development. New drug discovery and product launch in chronic metabolic disorders would provide fruitful opportunities for Peptide Therapeutics Market....
129 pages •
By Global Industry Analysts
• Aug 2021
Abstract: The ongoing Covid-19 pandemic has highlighted the potential for mRNA therapies. The mRNA technology has experienced decades of research efforts from scientists and various biotechnology companies. Discovered in the 1960s as an option to convert DNA codes into proteins, mRNA took several decades to emerge...
Executive Summary Global Gastroesophageal Reflux Disease (GERD) Therapeutics Market was valued at USD 5.5 billion in the year 2020. The key factors driving growth in the global Gastroesophageal Reflux Disease Therapeutics market is increased public awareness of the disease and its symptoms. The growing incidence of heartburn...
Gross Domestic Product
You can change your Cookie Settings at any time but parts of our site will not function correctly without them.